Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.

Although the rate of overall symptomatic hypoglycaemia during the maintenance period (primary endpoint) was lower with degludec U200 compared with glargine U300, the difference did not reach statistical significance.

also in 111,027 other papers